Enveric Biosciences

Enveric Biosciences (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogenic small-molecule therapeutics, revealed positive data from preclinical safety and pharmacology studies of its lead drug candidate, EB-003. The Massachusetts-based company announced that the results show the...

Psychedelics have shown promise in treating various mental health issues, including PTSD and depression, but they’ve often faced notable challenges. Side effects like nausea, cardiovascular risks, and the potential for "bad trips" have raised concerns among both clinicians and patients. As...

Enveric Biosciences, Inc. (NASDAQ: ENVB) released its corporate update and reported financial results for the first quarter of 2023 ending March 31, 2023. Q1 2023 Financial Highlights Net loss attributable to shareholders was $4.80 million for the quarter ended March 31, 2023, including $0.56...

Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental health conditions and how clinical data is crucial to pulling institutional...

  Enveric Biosciences Inc. (NASDAQ: ENVB) reported its financial results for the full year ended December 31, 2021. 2021 Financial Results Comprehensive net loss for the year was $48.8 million, including $36.3 million in net non-cash expenses, with a basic and diluted loss per share of $2.07...

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second...